George Goldsmith
About George Goldsmith
George Goldsmith is the Chairman and Co-founder committed to reducing mental health suffering through the development of the COMP360 psilocybin treatment for treatment-resistant depression.
George Goldsmith Chairman and Co-founder
George Goldsmith serves as the Chairman and Co-founder of a leading mental health organization. He is dedicated to leveraging evidence-based approaches to address mental health issues at scale. His strategic role involves guiding the company's mission and ensuring the overarching goals align with the commitment to reduce mental health suffering.
COMP360 Psilocybin Treatment Development
George Goldsmith is instrumental in developing the COMP360 psilocybin treatment, a promising investigational therapy for treatment-resistant depression. The treatment is currently undergoing a global phase 3 programme aimed at providing new solutions for people who have not responded to traditional therapies. His work reflects a high level of commitment and robust scientific inquiry to bring innovative treatments to the market.
Values: Compassion, Boldness, Rigour, and Inclusivity
Central to George Goldsmith's approach are the values of compassion, boldness, rigour, and inclusivity. These guiding principles shape his efforts in making mental health therapies accessible to all. His emphasis on inclusivity ensures that therapies are not only effective but also equitably distributed to those in need.
Commitment to Scientific Rigour and Integrity
George Goldsmith's commitment to the highest standards of scientific rigour and integrity is evident in all aspects of his work. He follows stringent scientific processes as recommended by regulatory agencies and ensures that both positive and negative clinical study results are published publicly. This transparency fosters a collaborative environment aimed at improving patient outcomes through shared knowledge and comprehensive research data.
Clinical Research Collaboration and Publication
George Goldsmith is dedicated to advancing science through collaboration. He encourages and supports the publication of all study results, including those from independent studies involving COMP360 psilocybin. His commitment to publishing complete data helps facilitate an open dialogue in the scientific community and aids in the collective effort to understand and improve mental health treatments.